Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION363 in FUS-ALS
NCT04768972Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Jun 2026
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing ION363 with Placebo (2 arms). Primary endpoint: Change from Baseline in functional impairment at Day 505. Started Jun 2021; status: active, not recruiting.
02
Drugs
ulefnersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04768972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768972.